Nicholas Cosford, Ph.D. is co-director and professor in the Cancer Molecular Therapeutics Program at Sanford Burnham Prebys’ Cancer Center. Cosford, in collaboration with colleagues at UC San Diego and Camino Pharma LLC, a San Diego-based biotechnology company he co-founded, has received a $9 million award from the National Institutes of Health (NIH) and National Institute on Drug Abuse (NIDA) to advance an investigational drug called SBP-9330 to Phase 2 clinical trials.
“Our drug, SBP-9330, works through a different mechanism distinct from currently available medicines,” says Cosford. “It’s taken orally. It may give people who want to quit smoking a new, safe, effective way to kick the habit.”
Негізгі бет Nicholas Cosford discusses the potential of a new, safe, effective way to quit smoking
Пікірлер